A phase II trial of biochemical modulation using N‐ phosphonacetyl‐L‐aspartate, high‐dose methotrexate, high‐dose 5‐fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site

Background. 5‐Fluorouracil (5‐FU) has modest activity as a single agent in a number of human adenocarcinomas. The technique of biochemical modulation has been used preclinically to increase the activity of 5‐FU. Methods. With doses based on a Phase I study, the authors performed a Phase II trial in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 1992-10, Vol.70 (7), p.1988-1992
Hauptverfasser:	Kelsen, David, Martin, Daniel S., Colofiore, Joseph, Sawyer, Robert, Coif, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	5‐fluoroura‐cil Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - secondary adenocarcinoma of unknown primary site Adult Antimetabolites, Antineoplastic - administration & dosage Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aspartic Acid - administration & dosage Aspartic Acid - analogs & derivatives biochemical modulation Biological and medical sciences Chemotherapy Drug Evaluation Female Fluorouracil - administration & dosage Humans Leucovorin - administration & dosage Life Sciences & Biomedicine Male Medical sciences Methotrexate - administration & dosage Middle Aged Neoplasms, Unknown Primary - drug therapy Neoplasms, Unknown Primary - metabolism Oncology PALA Pharmacology. Drug treatments Phosphonoacetic Acid - administration & dosage Phosphonoacetic Acid - analogs & derivatives Phosphoribosyl Pyrophosphate - metabolism Science & Technology Uridine Triphosphate - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!